PDCD1 and melanoma: There is an ongoing debate regarding whether LDH can be used to assess the prognosis of patients with melanoma treated with anti–PD-1/PD-L1 antibodies, because some evidence suggest that OS/PFS and pretreatment LDH have no significant correlation (20–22).